Meeting
2011 ASCO Annual Meeting
RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
Authors
S. Verstovsek
University of Texas M. D. Anderson Cancer Center, Houston, TX
S. Verstovsek , J. Kiladjian , R. J. Waltzman , V. Sandor , J. Lukawy , W. M. Garrett , K. Malek , R. M. Huber , A. M. Vannucchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT01243944
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS203)
Abstract #
TPS203
Poster Bd #
49A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).
First Author: Francesco Passamonti
Poster
2024 ASCO Genitourinary Cancers Symposium
Randomized phase III clinical trial of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms: Interim analysis.
First Author: Alberto Saita
Poster
2023 ASCO Breakthrough
Preclinical evaluation of JAK2 specific investigational oligonucleotide for the treatment of MDS/PV.
First Author: Bartlomiej Przychodzen
Poster
2023 ASCO Annual Meeting
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
First Author: Arvind Dasari